FY2024 EPS Estimates for CRVS Decreased by Cantor Fitzgerald

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) – Stock analysts at Cantor Fitzgerald decreased their FY2024 earnings per share (EPS) estimates for shares of Corvus Pharmaceuticals in a report released on Wednesday, November 13th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will post earnings of ($0.91) per share for the year, down from their previous estimate of ($0.50). The consensus estimate for Corvus Pharmaceuticals’ current full-year earnings is ($0.68) per share.

A number of other analysts have also weighed in on the stock. LADENBURG THALM/SH SH increased their price objective on shares of Corvus Pharmaceuticals from $12.00 to $21.00 and gave the stock a “buy” rating in a research report on Monday, September 16th. StockNews.com downgraded Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, October 31st. Mizuho upgraded Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 22nd. Finally, Oppenheimer increased their target price on Corvus Pharmaceuticals from $8.00 to $14.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $12.83.

Corvus Pharmaceuticals Trading Down 3.9 %

Shares of CRVS opened at $8.19 on Monday. Corvus Pharmaceuticals has a twelve month low of $1.30 and a twelve month high of $10.00. The company’s fifty day simple moving average is $6.83 and its 200-day simple moving average is $4.06. The company has a market cap of $526.26 million, a P/E ratio of -8.81 and a beta of 1.05.

Institutional Trading of Corvus Pharmaceuticals

A number of large investors have recently modified their holdings of the company. Geode Capital Management LLC increased its holdings in Corvus Pharmaceuticals by 22.4% during the 3rd quarter. Geode Capital Management LLC now owns 563,009 shares of the company’s stock worth $2,974,000 after purchasing an additional 102,869 shares during the period. XTX Topco Ltd purchased a new position in shares of Corvus Pharmaceuticals during the third quarter valued at $74,000. Jane Street Group LLC bought a new stake in shares of Corvus Pharmaceuticals in the third quarter valued at about $265,000. State Street Corp lifted its stake in Corvus Pharmaceuticals by 48.2% in the third quarter. State Street Corp now owns 178,246 shares of the company’s stock worth $941,000 after acquiring an additional 57,943 shares during the period. Finally, Nwam LLC bought a new position in Corvus Pharmaceuticals during the 3rd quarter worth about $53,000. Hedge funds and other institutional investors own 46.64% of the company’s stock.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.